Genfit S.A. (GNFTF) Stock Analysis

Genfit S.A. (GNFTF) Healthcare & Pipeline Overview

Genfit S.A. is a French biopharmaceutical company focused on developing drug candidates and diagnostic solutions for metabolic and liver diseases. With a pipeline including a Phase 3 candidate for primary biliary cholangitis and a diagnostic technology for NASH, the company targets areas of significant unmet medical need within the biotechnology sector.

What Is the Investment Thesis for GNFTF?

Genfit S.A. presents an investment thesis centered on its clinical-stage pipeline and diagnostic technology addressing significant unmet medical needs in liver and metabolic diseases. The company's lead asset, Elafibranor, currently in Phase 3 for primary biliary cholangitis, represents a key value driver, with potential for market entry if successful. The global market for PBC treatments is substantial, and a successful outcome in late-stage trials could significantly de-risk the asset and provide a clear path to commercialization. Additionally, the NIS4 technology, commercialized as NASHnext via a licensing agreement with Labcorp, positions Genfit in the growing market for non-invasive NASH diagnostics. This diagnostic solution offers a recurring revenue stream potential and strategic leverage within the broader NASH landscape. While the company operates with a significant negative profit margin of -127.4%, indicative of its research and development-intensive nature, its gross margin of 26.0% reflects some revenue generation, likely from licensing or early commercial activities. Future growth is contingent on successful clinical trial progression for GNS561 (Phase 1b/2 for CCA) and Nitazoxanide (Phase 1 for acute-on-chronic liver failure), which could expand its therapeutic reach. The company's $789M market capitalization and a Beta of 1.08 suggest a moderate correlation with overall market movements, typical for a biotechnology firm. The successful advancement and commercialization of its pipeline assets are critical for improving its financial profile and realizing long-term value.

Based on FMP financials and quantitative analysis

GNFTF Key Highlights

Market capitalization of $789M, reflecting its valuation as a clinical-stage biopharmaceutical company.

• Profit margin of -127.4%, indicating substantial investment in research and development activities typical for a biotech firm with a pipeline in development.
• Gross margin of 26.0%, suggesting some revenue generation, potentially from licensing agreements or early commercialization efforts.
• Beta of 1.08, indicating a moderate sensitivity to broader market fluctuations.
• Elafibranor, a lead drug candidate, is currently in a pivotal Phase 3 clinical trial for primary biliary cholangitis, representing a significant near-term value driver.

Who Are GNFTF's Competitors?

GNFTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GNFTF's Key Strengths?

Advanced clinical pipeline with a Phase 3 candidate (Elafibranor for PBC).

• Proprietary NIS4 diagnostic technology with a commercialization agreement (NASHnext with Labcorp).
• Strategic partnerships for development and commercialization of assets.
• Focus on therapeutic areas with high unmet medical needs.

What Are GNFTF's Weaknesses?

Significant negative profit margin (-127.4%), indicating high R&D costs and lack of profitability.

• Reliance on successful clinical trial outcomes, which are inherently uncertain.
• Trading on the OTC market, potentially limiting liquidity and investor access.
• Early-stage nature of several pipeline assets (Phase 1, Phase 1b/2).

What Could Drive GNFTF Stock Higher?

GNFTF catalyst: **Upcoming:** Successful completion and positive data readout from the Phase 3 clinical trial for Elafibranor in primary biliary cholangitis, leading to potential regulatory submission.

• **Upcoming:** Regulatory approval and subsequent commercial launch of Elafibranor for primary biliary cholangitis in key markets.
• **Upcoming:** Further expansion and adoption of the NASHnext blood-based molecular diagnostic test, commercialized through the licensing agreement with Labcorp.
• **Ongoing:** Progression of GNS561 through its Phase 1b/2 trial for cholangiocarcinoma, with interim data releases or advancement to later stages.
• **Ongoing:** Advancement of Nitazoxanide through its Phase 1 trial for acute-on-chronic liver failure, demonstrating safety and preliminary efficacy.

What Are the Key Risks for GNFTF?

Financial-distress signal — its Altman Z-Score of -1.63 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 5 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• **Potential:** Clinical trial failures or unexpected adverse events for Elafibranor, GNS561, or Nitazoxanide, which could halt development or lead to regulatory rejection.
• **Ongoing:** Significant negative profit margin (-127.4%) and high R&D expenses, indicating a continuous need for funding and potential for shareholder dilution.
• **Potential:** Intense competition in the metabolic and liver disease space from larger pharmaceutical companies with greater resources and established market presence.
• **Ongoing:** Regulatory hurdles and delays in obtaining approvals for drug candidates or diagnostic solutions, impacting commercialization timelines.
• **Potential:** Limited liquidity and transparency associated with trading on the OTC market, potentially affecting investor confidence and share price stability.

What Are the Growth Opportunities for GNFTF?

• **Advancement and Commercialization of Elafibranor for Primary Biliary Cholangitis (PBC):** Elafibranor is Genfit's most advanced drug candidate, currently in a Phase 3 clinical trial for PBC. A successful outcome in this pivotal trial, followed by regulatory approval, would unlock access to the global PBC treatment market. The market for PBC therapies is projected to grow, driven by increasing diagnosis rates and the need for more effective, well-tolerated treatments. Successful commercialization would provide Genfit with a significant revenue stream, transitioning the company from a purely R&D-focused entity to one with a marketed product. The timeline for this opportunity is contingent on trial completion, regulatory review, and market launch, potentially within the next few years.
• **Expansion and Adoption of NIS4 Technology for NASH Diagnosis:** Genfit's NIS4 technology, commercialized as NASHnext through a licensing agreement with Labcorp, targets the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. NASH is a silent epidemic, and the demand for non-invasive, accurate diagnostic tools is immense, as current methods often involve liver biopsies. The global market for NASH diagnostics is expected to grow substantially as awareness increases and new treatments emerge. Expanding the adoption of NASHnext globally and potentially developing further diagnostic applications for NIS4 beyond NASH represents a significant growth avenue, offering recurring revenue from licensing and sales.
• **Progression of GNS561 in Cholangiocarcinoma (CCA) Treatment:** GNS561, developed under a licensing agreement with Genoscience Pharma, is in a Phase 1b/2 trial for cholangiocarcinoma (CCA). CCA is a rare but highly aggressive cancer with a poor prognosis and limited treatment options, indicating a high unmet medical need. Successful progression through clinical trials and eventual market approval for GNS561 would position Genfit in the orphan drug market, which often commands premium pricing due to the severity and rarity of the disease. This opportunity, while earlier stage, offers substantial upside given the critical need for new CCA therapies.
• **Development of Nitazoxanide for Acute-on-Chronic Liver Failure (ACLF):** Nitazoxanide is in a Phase 1 trial for acute-on-chronic liver failure (ACLF), a severe and life-threatening condition. ACLF has high mortality rates, and effective therapeutic interventions are urgently needed. Advancing Nitazoxanide through clinical development could address a critical medical gap and tap into a market segment with high clinical urgency. While in its early stages, success in this program could provide a novel treatment for a devastating condition, offering significant humanitarian and commercial value. The long development timeline for this asset suggests a longer-term growth opportunity.
• **Strategic Partnerships and Pipeline Expansion:** Genfit's current licensing agreements with Labcorp and Genoscience Pharma demonstrate its capability to forge strategic collaborations. Future growth opportunities lie in securing additional partnerships for its existing pipeline assets, exploring new indications for its current drug candidates, or in-licensing novel compounds or technologies. Such collaborations can provide non-dilutive funding, leverage broader commercialization networks, and diversify the company's risk profile. Expanding its pipeline through strategic acquisitions or internal research into new metabolic or liver diseases could also fuel long-term growth, broadening its therapeutic and diagnostic footprint.

What Are GNFTF's Competitive Advantages?

• **Proprietary Drug Pipeline:** Exclusive rights to investigational drug candidates like Elafibranor, GNS561, and Nitazoxanide, protected by intellectual property.
• **Unique Diagnostic Technology:** Ownership and licensing of the NIS4 technology, offering a differentiated approach to non-invasive diagnosis of NASH and fibrosis.
• **Strategic Licensing Agreements:** Established partnerships with major players like Labcorp for diagnostics and Genoscience Pharma for therapeutics, leveraging their expertise and market reach.
• **Specialized Expertise:** Deep scientific and clinical knowledge in metabolic and liver diseases, a complex therapeutic area requiring specialized R&D capabilities.

What Does GNFTF Do?

Genfit S.A., incorporated in 1999 and headquartered in Loos, France, operates as a biopharmaceutical company dedicated to the discovery and development of innovative drug candidates and diagnostic solutions. The company's strategic focus lies in addressing metabolic and liver-related diseases, a therapeutic area characterized by significant unmet medical needs. Over its history, Genfit has evolved from a research-focused entity into a clinical-stage biopharmaceutical firm, building a pipeline of assets designed to tackle complex conditions. A cornerstone of Genfit's pipeline is Elafibranor, a drug candidate currently in a pivotal Phase 3 clinical trial for the treatment of patients suffering from primary biliary cholangitis (PBC), a chronic liver disease. Beyond therapeutic development, Genfit is also at the forefront of diagnostic innovation with its NIS4 technology. This proprietary technology is being developed for the diagnosis of nonalcoholic steatohepatitis (NASH) and associated fibrosis, conditions that represent a major global health challenge. The company has strategically leveraged its NIS4 technology through a licensing agreement with Labcorp, a global leader in diagnostic services, for the commercialization of NASHnext, a blood-based molecular diagnostic test aimed at facilitating earlier and more accurate diagnosis of NASH. Furthermore, Genfit's therapeutic pipeline extends to GNS561, an investigational treatment undergoing a Phase 1b/2 trial for cholangiocarcinoma (CCA), a rare and aggressive form of bile duct cancer. This program is advanced through a licensing agreement with Genoscience Pharma, underscoring Genfit's collaborative approach to drug development. Another early-stage asset in its portfolio is Nitazoxanide, which is in a Phase 1 trial for the treatment of acute-on-chronic liver failure, a severe condition with high mortality. With 180 employees, Genfit maintains its headquarters in Loos, France, as it continues to advance its diverse portfolio of drug candidates and diagnostic tools, aiming to provide solutions for challenging liver and metabolic diseases.

What Products and Services Does GNFTF Offer?

• Discovers and develops drug candidates for metabolic and liver-related diseases.
• Develops diagnostic solutions, such as the NIS4 technology for nonalcoholic steatohepatitis (NASH) and fibrosis.
• Conducts clinical trials for its drug candidates, including Elafibranor (Phase 3 for PBC), GNS561 (Phase 1b/2 for CCA), and Nitazoxanide (Phase 1 for ACLF).
• Engages in licensing agreements for the commercialization of its diagnostic tests, like NASHnext with Labcorp.
• Collaborates with other biopharmaceutical companies for the development and commercialization of investigational treatments, such as GNS561 with Genoscience Pharma.
• Focuses on addressing unmet medical needs in chronic liver diseases and severe metabolic conditions.

How Does GNFTF Make Money?

• **Drug Development and Commercialization:** Invests in R&D to discover and advance drug candidates through preclinical and clinical trials, aiming for regulatory approval and subsequent commercialization.
• **Diagnostic Solution Licensing:** Develops proprietary diagnostic technologies and licenses them to larger diagnostic companies for commercialization, generating revenue through royalties or upfront payments.
• **Strategic Partnerships:** Forms collaborations with other pharmaceutical or biotechnology companies to co-develop or out-license drug candidates, sharing development costs, risks, and potential profits.

What Industry Does GNFTF Operate In?

Genfit S.A. operates within the highly specialized and competitive biotechnology industry, specifically targeting metabolic and liver-related diseases. This sector is characterized by extensive research and development cycles, high regulatory hurdles, and significant capital requirements. The broader healthcare sector, particularly biotechnology, is driven by innovation and the pursuit of solutions for unmet medical needs. Genfit's focus areas, such as primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), and cholangiocarcinoma (CCA), represent markets with substantial patient populations and limited effective treatments, thus offering considerable market potential for novel therapies and diagnostics. The competitive landscape includes both large pharmaceutical companies with established liver disease portfolios and smaller, agile biotech firms developing specialized treatments. Genfit's strategy of developing both drug candidates and diagnostic solutions, such as the NIS4 technology for NASH, positions it uniquely by addressing both therapeutic and diagnostic gaps, potentially enhancing its market penetration and value proposition within this dynamic industry.

Who Are GNFTF's Key Customers?

• Patients suffering from metabolic and liver-related diseases, including primary biliary cholangitis, nonalcoholic steatohepatitis, cholangiocarcinoma, and acute-on-chronic liver failure.
• Healthcare providers (physicians, specialists) who prescribe or recommend treatments and diagnostic tests for these conditions.
• Diagnostic laboratories and healthcare systems that utilize and administer diagnostic tests like NASHnext.
• Pharmaceutical companies seeking to partner on development or commercialization of novel therapies.

Genfit S.A. (GNFTF) Valuation Context

Valued at $789M, GNFTF is classified as a small-cap stock.

GNFTF Revenue & Earnings Trend

In Q4 FY2025, GNFTF generated $31.9M in top-line revenue, marking a sequential decrease of 10.1%. The company recorded a net loss of $76.0M, with diluted EPS of $-1.52. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, GNFTF averaged $-0.45 in diluted EPS.

Company Profile

Genfit S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Loos, FR. The company is led by CEO Pascal Prigent. GNFTF has traded publicly since 2014.

Key Financial Metrics

Return on assets is -54.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.00 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -16.3%, the inverse of the P/E and a quick read on earnings relative to price.

Genfit S.A.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.63 places it in the distress zone, a signal of elevated financial risk.

Genfit S.A. has missed Wall Street's EPS estimate in 3 of its last 5 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 63.7% below estimates on average.

Wall Street analysts project Genfit S.A. revenue of about $95.3M for fiscal 2026, with EPS near $0.38. The estimate reflects 4 contributing analysts.

GNFTF Financials

GNFTF Latest News

GNFTF Analyst Consensus

GNFTF MoonshotScore

Genfit S.A. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources